PEGylated insulin Lispro (LY2605541): clinical overview of a new long-acting basal insulin analog in the treatment of Type 2 diabetes mellitus.

PEGylated insulin Lispro (LY2605541): clinical overview of a new long-acting basal insulin analog in the treatment of Type 2 diabetes mellitus. Expert Rev Endocrinol Metab. 2015 Jul;10(4):365-374 Authors: Røder ME Abstract Neutral Protamine Hagedorn insulin with an intermediate action profile has been in use for many years for the treatment of Type 1 diabetes and as an option for Type 2 diabetes. It is efficacious in reducing blood sugars, but shows substantial variability and risk of hypoglycemia. Basal insulin analogs have been developed in recent years to overcome these issues. Three basal insulin analogs are currently in the market in Europe. PEGylated insulin lispro is a new second-generation basal insulin analog which most likely will undergo review in 2016 by the US FDA and EMA in Europe for possible approval for marketing. Phase III trials are finalized, but not yet published. Phase II studies suggest antiglycemic efficacy, possible with a preferential hepato-specific action, a low rate of hypoglycemia, minor weight loss and acceptable tolerability. The benefit-risk profile needs, however, to be established. PMID: 30293492 [PubMed]
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research

Related Links:

ConclusionsMost patients with DKA presented with mild and moderate DKA and only a minority presented with the severe form of the disease. The etiology of DKA was mainly T1DM and less frequent uncontrolled T2DM, usually due to the co-existence of severe infections, while only in a tiny minority, the causes remained unidentifiable.
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research
Publication date: Available online 15 March 2019Source: Journal of Pharmacological SciencesAuthor(s): Sheng-gao Tang, Xiao-yu Liu, Shan-ping Wang, Hong-hui Wang, Aleksandar Jovanović, Wen TanAbstractDiabetic cardiomyopathy (DCM) is characterized by cardiac hypertrophy, fibrosis, oxidative stress and inflammation. Trimetazidine (TMZ), a potent metabolism modulator, has been shown to be cardioprotective in experimental models of ischaemia-reperfusion and type 2 diabetes-induced cardiomyopathy. The present study examined whether TMZ inhibits cardiomyopathy induced by insulin-dependent type 1 diabetes. Wistar rats were random...
Source: Journal of Pharmacological Sciences - Category: Drugs & Pharmacology Source Type: research
Diabetes mellitus is a chronic and complex disease affecting over 30.3 million people in the United States [3]. As a chronic disease, diabetes requires intensive monitoring and management on the part of patients and their healthcare providers. Both type 1 and type 2 diabetes are associated with acute and long-term medical complications and comorbidities including neuropathy, retinopathy, diabetic cardiomyopathy, and overall mortality (e.g., [24,30]. Diabetes is also associated with multiple co-morbid psychological conditions such as depression and anxiety as well as psychological conditions that are specific to the disease...
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Source Type: research
Publication date: Available online 10 March 2019Source: NeuroscienceAuthor(s): Sabine Paeschke, Petra Baum, Klaus V. Toyka, Matthias Blüher, Severin Koj, Nora Klöting, Ingo Bechmann, Joachim Thiery, Joanna Kosacka, Marcin NowickiAbstractPeripheral diabetic neuropathy (PDN) is one of the common complications of diabetes mellitus. Previous studies showed an association between dietary iron load and inflammation in the development of PDN in a rat model of type 1 diabetes (T1D). Here we investigated the role of iron and neural inflammation in development of PDN in the animal model of obesity and type 2 diabetes (T2D)...
Source: Neuroscience - Category: Neuroscience Source Type: research
CONCLUSION: LADA presents a mixed cellular immunological pattern with features overlapping with both T1D and T2D. This article is protected by copyright. All rights reserved. PMID: 30843600 [PubMed - as supplied by publisher]
Source: Clinical and Developmental Immunology - Category: Allergy & Immunology Authors: Tags: Clin Exp Immunol Source Type: research
CONCLUSIONS: The successful development of any drug delivery systems relies on solving three important issues: toxicity of nanoparticles, stability of nanoparticles, and desired drug release rate at targeted sites. The main goals of future investigations are to improve the existing therapies by pharmacokinetic modifications, development of a fully automatized system to mimic insulin delivery by the pancreas and reduce invasiveness during admission. PMID: 30848184 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research
CONCLUSION: Although new data is evolving on the relation between DNA methylation, protein misfolding, and the etiology of diabetes, more studies are required for developing new relevant diagnostics and therapeutics. PMID: 30834843 [PubMed - as supplied by publisher]
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - Category: Endocrinology Authors: Tags: Endocr Metab Immune Disord Drug Targets Source Type: research
Over the last three decades, trials of coronary revascularization have taken into account whether populations did or did not have diabetes. What has not been considered is whether or not patients with diabetes in these studies have type 1 or type 2 diabetes. ‘Diabetes’ appears to be largely used as a synonym for type 2 diabetes. The number of patients with type 1 diabetes has not been reported in most trials. Many questions remain unanswered. Do patients with type 1 diabetes have the same response to various modes of revascularization as those with type 2 diabetes? We know type 2 diabetes affects coronary endot...
Source: Cardiovascular Endocrinology - Category: Cardiology Tags: Review articles Source Type: research
In this study we evaluated patient-reported outcomes of an investigational newly re-engineered 4  mm × 32G PN, the BD Nano™ 2nd Gen (also known by its “PRO” brand extension in many markets outside of the USA). In place of a conventional cylindrical posted hub, the investigational PN’s hub is contoured with an expanded surface area. The investigational PN also includes a redesigned i nner shield that includes tactile ridges and a remodeled outer cover with improved proportions and attachment grips.MethodsThis was a multi-site, prospective, open-label, two-period crossover trial. Ind...
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
Purpose: To assess and compare early modifications in inner retinal layer thickness and optical coherence tomography angiography parameters in patients with diabetes mellitus (DM) Types 1 and 2 without clinical signs of diabetic retinopathy. Methods: Ninety eyes of 90 subjects (24 Type 1 DM, 36 Type 2 DM, and 30 healthy controls) were prospectively evaluated with spectral domain OCT, swept-source OCT angiography, and color fundus photography (on the same day). Retinal nerve fiber layer, ganglion cell layer (GCL+), and nerve fiber layer + GCL+ (GCL++) thickness were automatically determined by the instrument in the 1, ...
Source: RETINA - Category: Opthalmology Tags: Original Study Source Type: research
More News: Diabetes | Diabetes Mellitus | Diabetes Type 1 | Diabetes Type 2 | Endocrinology | Humalog | Insulin | Marketing | Study | Sugar | Weight Loss